The 10 most influential leaders in medtech companies 2020 september 2020; Insights Succcess has published Magazine on 10 Most Influential Leaders in MedTech Companies in the September 2020.
Escorts in Nungambakkam Phone 8250092165 Enjoy 24/7 Escort Service Enjoy Your...
The 10 Most Influential Leaders in MedTech Companies 2020 September 2020
1. Med
Companies 2020
THE 10 MOST Influential Leaders in
Goliath
Technologies
MONITORING AND
TROUBLESHOOTING
END-USER EXPERIENCE
Insight Tech
Florence
Huckert
Tech View
Ensuring
Healthcare
Equity
+
Thomas
Charlton
CEO &
CHAIRMAN
VOL 09 | ISSUE 10 | 2020
2.
3.
4. Serving to
Humanity
he deadly coronavirus outbreak in the
TWuhan, now termed as COVID-19, and its
quick spread to the world, endangers
thousands of lives. The event has catalysed the
development of coronavirus vaccines. In the biotech
industry, both pharmaceutical companies and
research organisations are using their potential to
develop coronavirus vaccines or antivirals for
treating the coronavirus infection.
Medicine is one of the most reputed and
collaborative disciplines, and there was an
individual Edward Jenner without contributions of
his medical care today would be very different. In
1796, British surgeon and naturalist Edward Jenner
was the one who developed the first vaccine, the
vaccine of smallpox. Jenner was motivated to
develop the practice of vaccination after observing
that milkmaids who infected by cowpox never
developed smallpox. He injected the son of his
gardener with the cowpox, and in the results the boy
failed to catch smallpox after being exposed
repetitively to infected smallpox material. This was
the millstone in the field of immunology and the
first vaccine as well.
Today the definition of medical advancements has
changed as medical technology, or “medtech”,
comprises a wide range of healthcare products and
is used to treat diseases, save lives or transform the
health of individuals suffering from a varied range
of conditions. In its many forms, medical
technology is already analysing, monitoring and
handling virtually every disease or condition that
affects humans. At present time, medical technology
Editor’s Desk
A real advancement
consists vision for all
5. includes medical appliances, wearable and vitro
diagnostic medical devices.
So, in this edition, ‘The 10 Most Influential
Leaders in MedTech Companies 2020’ Insights
Success has shortlisted business leaders from
Medical and Healthcare industry who are
improving the quality of healthcare and
visioning to avail advance medical devices,
information technology, biotech, and healthcare
services.
Also, while flipping the pages, don’t forget to
go through the articles and CXOs written by
our in-house editorial team and industry experts
respectively.
rohit.chaturvedi@insightssuccess.com
7. 20
22
30
36
48
44
32
Triox Nano
Pioneers in point of care
programmable medicine!
presenting the next
healthcare revolution!
CMIC Inc.
Leading Treasure in Healthcare Industry
Especially in Pharmaceutical Sector
CereSoft
Energizing Healthcare
Cash Flow
Abionic SA
Revolutionizing the
World of In Vitro
Diagnostics
Allscripts
Building Open &
Connected
Communities of
Health
ClinCapture
A Sweeping Wave of Big
Data Innovation in the
Pharmaceutical Industry
Metrendalytics
Combining Knowledge and
Technology to Bring
Efficiency in Business
C O N T E N T S
10. Management Brief
Company Name
Paul Black
CEO
ClinCapture
clincapture.com
Hsing-Hen Chen
CEO
CMIC
cmicgroup.com
Triox Nano
f6s.com
Jan Miotto
President
Roy Farfara
MD, Founder & CTO
Jenny Lin, Chief
Operating Officer &
Board Member
Abionic
abionic.com
CereSoft
ceresoft.com
Metrendalytics
metrendalytics.com
Allscripts
allscripts.com
Scott Weidley
CEO
Abionic, an in vitro diagnostics (IVD) company, is aiming to
make a difference in patient care through the cutting-edge
nanofluidic technology based ultra-rapid diagnostic platform,
helping healthcare professionals to make clinical decisions at
the point of care.
Allscripts knows providing excellent healthcare while striving
to achieve business and operational goals. It is embracing all
aspects of the healthcare industry while thriving within its
constant evolution.
CereSoft is a healthcare revenue cycle management services
company based in Silver Spring, Maryland. It processes
millions of healthcare transactions daily for some of the most
high profile healthcare providers and financial institutions in
the United States.
Fundamentor is an innovative web application that enhances
the Quantitative, Verbal, Data inference and Creative thinking
aptitude in school students.
CMIC, Inc. leading CRO (Contract Research Organization) and
a provider specialized in bioanalytical services, whose cutting-
edge capabilities and sophisticated expertise in various aspects
helped it achieve a greater stature in the business.
Metrendalytics Consulting, focused on helping companies
develop highly customized and flexible business intelligence
solutions.
Triox Nano’s management describes its impeccable journey to
become the first biotech company to develop a modular
programmed drug delivery platform.
Nicolas Durand
Founder and CEO
Azuba Corporation
azuba.com
Bart Carlson
CEO and
Chief Patient Advocate
Azuba is an independent, cloud-based health-information
platform, which enables patients, providers and payers to
securely use comprehensive health information - anytime,
anywhere - leading to improved health outcomes.
Hemostemix
hemostemix.com
Thomas Smeenk
CEO
Hemostemix is a clinical-stage biotechnology company focused
on developing and commercializing a proprietary autologous
cell therapy to treat ischemic diseases.
Goliath Technologies
goliathtechnologies.com
Goliath Technologies offers end user experience monitoring
and troubleshooting software, with embedded intelligence and
automation, that enables IT pros to anticipate, troubleshoot, and
document performance issues regardless of where workloads,
applications, or users are located.
Thomas Charlton
CEO
14. Goliath offers the ability to continually test application availability delivered via Citrix or VMware Horizon from
remote locations. The technology then proactively alerts Health IT if an application or the delivery infrastructure is
down or slows so you can resolve before medical staff are impacted.
15. exposed to the technology industry, and I began to read
every book I could on the market and the major players. It
appeared an exciting and inviting meritocracy. People didn't
care about your level of education, background, or anything
subjective. The key to advancing was performance. I left
my executive level position in US Surgical and took a
position as a regional manager at Legato Systems. After a
year, I left Legato Systems for the VP of Sales position at
Tidal Software and eighteen months later I was appointed
CEO of that same company. I was CEO of five more
venture-backed companies, after which I founded Goliath
Technologies. Now I have merged my healthcare and
software knowledge by adapting our technology for the
healthcare marketplace to specifically focus on improving
end user and clinician experiences related to the major EHR
applications Epic, MEDITECH, Allscripts, and Cerner.
Today, we are known as the Health IT standard by our
clients and competitors.
How do you diversify your organization's offerings to
entice the target audience?
Diversification is certainly one way to entice a target
audience. While our technology is decidedly cross vertical,
our healthcare clients require purpose-built technology to
solve very specific issues faced by today's Health IT
departments. An enterprise IT department will have twice
the budget and people to support the same number of users
as the same department in a health system. And, in Health
IT, patient care is ultimately in the balance if IT systems
don't perform optimally. In the products we developed for
Health IT we made very deliberate decisions to add features
that help our Health IT professionals address challenges
that are unique to their situation. Specifically, we developed
integration and support for the clinical and business
applications that are critical to their end users along with
automation and embedded intelligence that has the net
effect of adding three full-time employees to their staff.
Have you drawn professional inspiration from other
business leaders? Tell us about someone who has
inspired you.
I was very fortunate in this regard. I had three men who
both inspired and taught me how to lead an organization.
First, my father, who was an accomplished business leader
himself in the steel and manufacturing industry. He imbued
me with the foundational personality traits that every leader
should possess. Then, I met Carlos Babini at US Surgical
With the intent of offering end-user experience
monitoring and troubleshooting software, with
embedded intelligence and automation, that
enables IT pros to anticipate, troubleshoot, and document
performance issues regardless of where IT workloads,
applications, or users are located, Goliath Technologies
came into existence. The organization believes, most
organization simply don't have enough time, tools, and staff
to troubleshoot every end-user ticket or complaint. This is
where Goliath comes in. With its embedded intelligence
and automation, the company proactively look for events,
conditions and failure points that precipitate end user
experience issues. Goliath Technologies also provides broad
and deep visibility across the delivery infrastructure (Citrix
or VMware Horizon), hypervisor, servers, operating
systems and applications to quickly identify where end-user
performance problems occur and what is causing them.
As the Chairman and CEO, Thomas Charlton is
responsible for the strategic direction and global expansion
of Goliath Technologies.
He has most recently orchestrated the turnaround at PHD
Virtual as Chairman and CEO. After multiple CEO's, the
majority shareholder, Insight Venture Partners, brought in
Mr. Charlton from Shunra Software, another portfolio
company. Seven record quarters of growth followed from
Q3 2010 to Q1 2012 driven by the acquisition of four new
customers per business day. During this time, Insight
Venture Partners and a new investor, Citrix Systems,
provided additional equity financing. PHD Virtual was
acquired by Unitrends in 2013.
In an interview with Insights Success, Thomas Charlton, the
CEO and Chairman of Goliath Technologies, has shared
key insights of the struggles and journey of the
organization.
Below are the highlights of the interview between Insights
Success and Thomas Charlton;
Kindly take us through your journey on becoming a
proficient med tech leader.
I began my career in healthcare working for US Surgical.
We offered stapling instruments that dramatically shortened
the time it took to complete a surgical procedure which
improved patient outcomes while lowering costs. As my
career progressed, I moved out West to San Francisco in the
middle of the dot-com boom. For the first time I was
The 10 Most In luential Leaders in MedTech Companies, 2020
16. who, by example and teaching, showed me how to manage
teams and practice leadership. Carlos was especially
effective at turning around failing divisions for the
company. He was effectively the go-to executive that was
put in charge when parts of the business were not
performing. He educated me, over years, on how to lead
teams through a crisis in leadership and back to acceptable
business performance. Finally, Lacy Edwards, Chairman of
the Board at Tidal Software, taught me how to be a CEO of
a venture-backed software company. He offered me very
specific direction on tactics, strategy, and code of conduct.
These gentlemen were all equal parts demanding and
instructional. Each of these men, all very accomplished,
took time that could have been spent elsewhere and shared
it with me. For that I am both fortunate and eternally
grateful.
What values are important to you as a business leader?
I think a good business leader needs to operate with
integrity, empathy, and courage. Most tech firms, especially
software, are successful because of the sum contributions of
their people. Without these core values, I don't think you
can effectively build or lead a great team in a sustainable
fashion.
How do you achieve work-life balance?
I think stress is created as a result of people's unrealistic
expectations of and desire to achieve, so called work-life
balance. If creating an even balance between one's personal,
professional, and financial goals is the objective then that is
one thing. However, if one desires to achieve something
great, above average, and certainly if you want to lead your
own company, then the relative emphasis and
corresponding time spent in these three areas is going to
change over time. Read a story about the leaders of any
great tech company, whether it is HP, Oracle, Microsoft,
Apple, or Amazon, and it is manifestly evident that
prioritization across these three life areas was not equal and
therefore out of balance at certain times. But their goal
wasn't balance it was achievement.
What was your life changing event/incident that
changed your life?
There were a number of them in my personal and business
journeys. One, that I reflect upon often, occurred when I
was going to visit a friend of mine who was attending an
Ivy League University. It was homecoming at the university
and I made the drive with his father to visit. The
conversation turned to careers during the drive. He
suggested, given that I was only attending a community
college, I finish my two years and then build the lawn
mowing business which I had through high school and
college. His opinion was that without an Ivy League
education I was relegated to a career of tending to the lawns
of more educated men. I was more than mildly upset and
insulted at the time but didn't have the benefit of experience
yet to know that people will attempt to set expectations for
you based on their own prejudices, insecurities, and
limitations, not your best interest or potential. In the United
States, we have no caste system, royal family, or contrived
subjective impediments that seek to prevent certain groups
of people from advancing their position. In this country
what you expect of yourself, and the desire to achieve, are
the only limiting factors to success.
How necessary is it to align business with technology
and what are its outcomes?
It is critical because technology has no value without that
alignment. Successful technology companies enable better
business outcomes. In fact, many technologies and
technology companies fail do so because there isn't a
business benefit, or large enough one, to create sustained
demand for the product or service.
What are your future endeavors/objectives and where
do you see the medical industry in the near future?
This is a question that is difficult to answer in today's
environment. Emergency room visits have almost
evaporated and that isn't revenue health systems will get
back. At the same time, elective surgeries have been
suspended. It is a gross understatement to say this is a
challenging time for health systems. Based on
conversations with our health system clients, we see an
acceleration towards technical solutions that will enable the
provisioning of healthcare remotely. Telehealth is one such
example. Health systems that had one hundred telehealth
visits a few months ago are now seeing thousands. This is a
real opportunity for tech companies to serve ongoing
patient care by advancing their remote enablement
technology. As with any crisis, there will be opportunity
created for those who have the vision, awareness, and
capability to act.
19. What advice would you like to give to the emerging tech
leaders?
This is a broad question given the number of areas on
which to offer advice. From a purely business perspective
there are three key pillars that support a successful
company. They are marketplace, technology, and business
execution. The first is most important because we don't
have the power to change it where, with time and capital,
you can impact the other two pillars of success. In my years
with venture capital, I would say most companies failed
because there was either no market or not a large enough
market for the technology to allow sustained growth.
People tend to become enamored with technology and
business plans. Neither of those will matter without a
market pull for the technology. I look for known markets
with incumbent competitors where I can introduce a
technology that has a price or performance advantage that
can be utilized by companies that are underserved by the
current solutions.
Goliath Technologies, the standard in Health IT, provides an end-to-end view that enables Health IT
to bring end-user experience, delivery infrastructure, and EHR application metrics together to
anticipate, troubleshoot, and document issues within the Clinical Virtual Workspace.
20.
21.
22. In 2009, more than 100 million Europeans suffered
from allergies. Ironically, the sharp rise in allergy-
related conditions of recent decades can be traced
back to improved hygiene. European public health
systems have identified this surge as one of the main
factors that put pressure on their infrastructure.
In the biomedical field, the demand for reliable, fast, and
inexpensive products to diagnose allergies continued to
grow. With this finding, Dr. Nicolas Durand and Dr.
Iwan Märki launched Abionic.
They developed an advanced diagnostic platform that
can quickly obtain a patient’s personalized allergy
profile. This in vitro test, which has been designed to be
simple, reliable and cost-efficient, is an alternative to
expensive blood tests performed in laboratories that are
currently used to identify allergies.
Since its establishment, Abionic has used these highly
advanced technologies with a vision to improve
healthcare and enhance the wellbeing of the patient.
Committed to Medical Innovation
In Vitro Diagnostics (IVDs) are medical devices and
accessories used to perform tests on samples, e.g., blood,
urine and tissue that have been taken from the human
body, to detect infections, diagnose medical conditions,
and prevent diseases.
Abionic is committed to revolutionize the world of in
vitro diagnostics with rapid universal point-of-care
solutions. It develops and produces tests that have
proven to be game-changers in each of their respective
markets. Furthermore, they allow access to lab-quality
blood analysis even where there is limited infrastructure
in place.
Abionic utilizes the most advanced technology to supply
healthcare professionals with a novel diagnostic tool. Its
products, the abioSCOPE (the reader), abioGUIDE (the
application for smartphones and tablets), and the tests
containing nanofluidic sensors have been developed and
are assembled by the company in Switzerland.
A Dynamic Young Leader
In 2010, Nicolas Durand, Founder and CEO of Abionic
was fresh out of EPFL with a Ph.D. in nanotechnology
when he launched Abionic in collaboration with Iwan
Märki. The firm was set up to build on Durand’s doctoral
Abionic SA
Revolutionizing the
World of In Vitro
Diagnostics
Dr. Nicolas Durand
Founder & CEO
20 | September 2020 www.insightssuccess.com
The 10 Most In luential Leaders in MedTech Companies, 2020
23. Agency, on top of being an active
infantry officer in the Swiss army.
Rapid and Reliable Point-of-care
Solutions
Abionic takes established and trusted
diagnostic principles to the point of
care so patients can get their results
immediately. Recently, the company
announced the CE marking of the
world’s most rapid test for the early
diagnosis of sepsis and treatment
management.
With an annual death toll of more
than 6,000,000, sepsis kills more
people than breast cancer, prostate
cancer, and AIDS combined. Many
of these deaths could have been
avoided if the condition had been
diagnosed and treated earlier.
Abionic’s PSP test, which is an aid at
diagnosis patients at risk of
developing sepsis in real-time has the
remarkable potential to save millions
of lives.
The Pivotal Movement
Abionic has had its sights set on
international expansion since 2012,
when it obtained ISO 13485
certification, an important mark of
credibility and a requirement to sell
medical devices in the European
Union.
The same year, the firm attracted its
first investors with a Series ‘A’
financing round that brought CHF
3.5 million in cash. Two years later,
the first healthcare professionals –
mainly doctors – contacted the
company to test their technology.
Abionic had to prove that its
nanotechnology could perform as
research, which aimed to develop a
nanofluid-based system that could
speed up blood test diagnostics.
Nicolas has also been involved in the
development of resonating
biosensors at Carnegie Mellon
University (USA).
He is the winner of the 2006 Omega
Award as well as more than 20
entrepreneurial awards, including the
2010 Young Entrepreneur Award.
Nicolas has earned a private pilot’s
license and was an astronaut
candidate for the European Space
promised and did so at the first
clinical trials which followed. That
was closely followed by a Series ‘B’
financing round with Swiss and
European entrepreneurs. By then,
Abionic’s prototype had become a
viable product; in 2016, the firm
began demonstrating commercial
traction by selling its devices to the
market.
Recently, the Series ‘C’ round was
closed to secure financing of clinical
impact studies and the development
of further tests.
Today, the entire production chain is
located in Switzerland and based in
Lausanne. It has the capacity to
produce up to one million test kits
per year.
International Expansion
Abionic envisions revolutionizing the
world of in vitro diagnostics with
rapid universal point-of-care
solutions powered with disruptive
nanotechnology. To demonstrate the
test’s medical and economic impact,
the company currently carries out a
large-scale clinical trial of its sepsis
tests in fourteen sites across Europe.
Abionic aims to expand its business
internationally and is working on the
development of further innovative
and impactful tests.
We use the
most advanced
nanotechnology
to supply
healthcare
professionals
with a novel
diagnostic tool
and, thereby,
bringing the
treatment
closer to
the patient.
21
|
www.insightssuccess.com September 2020
24. Allscripts is a leader in healthcare information
technology with a 30-year history of excellence.
The company has a vision to build open and
connected communities of health that advance clinical,
financial and operational results.
Its innovative solutions connect people, places and data
across its vision of an Open, Connected Community of
Health™. This connectivity empowers caregivers to
make better decisions and deliver better care for
healthier populations.
Allscripts creates tools that address virtually every aspect
of population health, an each of these tools facilitates
real-time analysis and action. They enable healthcare
organizations to analyze and act – right at the point of
care – to empower change, improve health, and reduce
costs.
CareInMotion™ is the company’s comprehensive
population health platform. It brings together care
coordination, patient engagement, connectivity, data
aggregation, and analytics at the point of care.
A Veteran Leader
Paul Black currently serves as a board member and the
CEO of Allscripts. Paul leads the company in its
commitment to build open, connected communities of
health.
Prior to joining Allscripts in 2012, Paul spent more than
13 years with Cerner Corporation in various executive
positions and retired as its CEO in 2007. During his
tenure, he helped build the company into a market leader
in healthcare information technology with more than
$1.5 billion in annual revenue.
Paul also spent 12 years with IBM Corporation in a
variety of leadership positions in sales, product
marketing, and professional services. He has served on
the boards of several private companies and nonprofit
organizations involved in healthcare information
technology, healthcare services, and consumer Internet
marketing.
He is currently the immediate past chairman and an
officer of Truman Medical Centers, a 400-bed safety net
academic hospital in Kansas City, MO. Paul holds a
CEO & Board Member
Paul Black
22 | www.insightssuccess.com
The 10 Most In luential Leaders in MedTech Companies, 2020
September 2020
25. community through open and interoperable solutions
that empower communication, collaboration, and
coordination for better outcomes.
Ÿ Innovating to improve the practice of medicine and
the process of care delivery.
Superior Patient Engagement
Allscripts believes that healthcare doesn’t begin and end
with just providers and patients, and it is the only
company that brings all healthcare stakeholders together.
By collaborating with payers, health plans and programs,
pharmaceutical and life sciences companies, and
employers, Allscripts has gained a wider view of the care
process. It uses that perspective to create innovative tools
that lower costs and improve care.
Allscripts offers the industry’s only vendor-agnostic
patient engagement platform. With the advantage of
open access across the care community, providers can
communicate effectively and engage patients directly,
creating game-changing improvements in patient
outcomes and operational performance.
Allscripts believes that the patient is at the center of
everything it does. Modern healthcare consumers
understand the benefits of engagement, and they expect
to be active participants in their own care. The
organization partners with providers to deliver an
improved patient experience where individuals have a
greater say in the treatment they receive.
With Allscripts, healthcare organizations have at their
disposal the critical tools required for ongoing
communication, effective education, and regular
interaction with patients. These tools make it easy for
caregivers to engage and quickly respond to consumers
while also offering them full, immediate access to their
healthcare information.
Evolving and Overcoming Challenges
When Allscripts was founded in 1986, its primary
business was repackaging medication for point-of-care
distribution. In the 1990s, Allscripts started transforming
the doctor’s office with comprehensive practice
management and electronic health record (EHR)
solutions.
Bachelor of Science degree from Iowa State University
and a Master of Business Administration degree from the
University of Iowa.
Committed to Client Success
Allscripts is the original open, connected health
platform. Thousands of the top hospitals, health systems,
physician’s practices, and healthcare facilities use the
company’s EHR, financial management, and population
health management solutions.
As a true healthcare IT innovator, Allscripts introduced
the concept of an open platform connecting all points of
the care community over a decade ago in 2007. The
organization provides advanced, reliable, client-focused
solutions that enable smarter care to be delivered with
greater precision. This makes for healthier patients,
populations, and communities.
The organization contributes to its clients’ success by:
Ÿ Strengthening their IT foundation through the most
comprehensive and user-friendly clinical and
financial solutions available today.
Ÿ Providing insights and innovations so they can meet
the operational, regulatory and quality demands of
today’s - and tomorrow’s - healthcare environment.
Ÿ Connecting everyone across the healthcare
““
23
|
www.insightssuccess.com September 2020
26. 24 | www.insightssuccess.com
To address fragmented care delivery, Allscripts merged
with acute-solution leader, Eclipsys in 2010. In 2013,
Allscripts took several significant steps to solidify and
advance its population health management solutions.
This included the acquisition of dbMotion, a leading
supplier of community health solutions, and of Jardogs,
the developer of FollowMyHealth, a patient engagement
solutions provider.
Looking to the future of healthcare, Allscripts launched a
wholly-owned subsidiary, 2bPrecise, a genomic and
precision medicine platform, in 2016. In October 2017,
the company acquired Enterprise Information Solutions
(EIS), the McKesson Corporation’s hospital and health
system IT arm.
This transaction significantly expanded their client base
in U.S. hospitals and health systems, and diversified its
solutions portfolio.
Today, Allscripts is a team of more than 7,000 devoted to
fulling the needs of providers today and creating the
health IT architecture of tomorrow.
The healthcare IT industry is extremely competitive and
Allscripts distinguishes itself by creating tools that
facilitate real-time analysis and action. Its solutions
enable healthcare organizations to analyze and act – right
at the point of care – to empower change, improve
health, and reduce costs.
In addition, the company addresses virtually every aspect
of population health. Allscripts provides a
comprehensive population health platform, brings
together care coordination, and promotes patient
engagement, connectivity, data aggregation, and
analytics at the point of care.
The Future Roadmap
Allscripts acknowledges that it is becoming increasingly
difficult to retrofit EHRs to take full advantage of new
innovations such as the Cloud, artificial intelligence, and
mobility. The organization believes that machine
learning will be a critical element in the evolution of
EHRs.
Allscripts built its latest EHR from the ground-up using
human-centered design. This platform is set to transform
the way physicians experience and interact with
technology, as well as improve provider wellness.
Machine learning capabilities incorporated into the
system identify client treatment patterns. It can pre-
populate information based on these patterns and deliver
preference reminders. By constantly tracking user,
organization, and region trends, it creates opportunities
for more efficiency.
The power of artificial intelligence reveals information
relevant to a patient-provider encounter in real time, and
this helps improve the quality and speed of interaction
with the patient. Ultimately, this reduces the amount of
time spent on documentation, helping address the
problems of “EHR fatigue” and physician burnout.
Allscripts is incorporating EHR-agnostic, precision
medicine, and genomic capabilities within providers’
workflows. This will help capture and store genomic data
from a range of sources, harmonize clinical knowledge
and genomic research to identify relevant information,
and then push the resulting insights to the point of care to
better determine the most effective regimen for the
patient.
““
September 2020
32. The healthcare sector is in a state of constant flux
and institutions are under tremendous pressure
to deliver high-quality patient results while also
maintaining desired profit margins. They have to balance
these requirements while adhering to a growing array of
regulatory specifications and other dynamic forces. In
this scenario, maintaining financial stability is a
challenging but essential task.
Hospitals and healthcare systems are recognized for
treating patients and saving lives but every healthcare
organization also has an obligation to remain financially
viable. Healthcare revenue cycle management plays a
crucial role here.
Healthcare revenue cycle management is the financial
process that facilities use to control and oversee
administrative and clinical functions connected with
processing claims, cyclic payments, and income
generation. The process includes the identification,
management, and collection of patient service revenue.
CereSoft’s Revenue Cycle Transformation works with
healthcare providers to help them recognize ways to
boost their net income, accelerate cash flow, and
decrease costs by addressing people, process, and
technology components across the revenue cycle
spectrum.
Thought Leadership in Healthcare and Technology
CereSoft is a technology pioneer and forward-thinking
company based in Silver Spring, Maryland. It was
founded in 1994 and today has over 200 employees
worldwide. CereSoft can handle the revenue cycle needs
of both large hospital systems and physician networks.
For over 20 years now, has been creating
the company
feature-rich, real-time digital exchanges with its clients
in the healthcare industry, while demonstrating thought
leadership in both healthcare and technology services
throughout the United States.
CereSoft’s one-stop solution for healthcare revenue
cycle management is spearheaded by its flagship product
and web portal, MedAR. MedAR allows users to handle
correspondence, financial analysis, denials,
underpayments, refunds, dependent claims, re-
associations, and other critical online functions within a
single system.
MedAR provides complete revenue cycle transformation
for medical practices as well. Its financial management
On-line Navigation System reduces the time required to
process manual posting to billing systems, denial
processing days, manual keying of transactions, and the
time required to balance.
Energizing Healthcare
Cash Flow
Dr. Hsing-Hen Chen
President & CEO
The 10 Most In luential Leaders in MedTech Companies, 2020
30 | www.insightssuccess.com
CereSoft
September 2020
33. A Single View Portal with Touch
and Feel Design
CereSoft is constantly seeking true
partnerships. More than 80% of its
portal is connected with its users, and
the touch-and-feel architecture of the
platform is a result of their valuable
feedback.
Clients expect a ‘Single View’
platform that can handle both paper
and electronic formats, as well as
structured and un-structured data in a
single application. CereSoft offers a
true virtual work desk where every
employee has access to a Single
View of all financial transactions.
The integration of all fragmented
components and document types in
one platform allows clients to search,
retrieve and view all data and file
sources on a single system. This
leads to performance characterized
by high speed, accuracy, reliability
and efficiency.
CereSoft has the finest sales and
marketing organization in the country
that are not sales-based people; they
are consultants that provide problem
solving techniques to all their
customers and business partners.
Visionary Leadership in an
Evolving Industry
Dr. Hsing-Hen Chen is President,
Founder and CEO of CereSoft.
Dr. Chen has an unusual background
for this industry. He has been a full-
time professor in Physics at the
University of Maryland for the past
40 years, and started off as an expert
in non-linear complex systems that
include neural networks, and deep
learning AI systems in particular.
This unique background led him into
It also allows the provider to view
any electronic document with a
single touch. CereSoft’s great
references, functionality, and ability
to complete the paper conversion to
EDI processing in less than 24 hours
helps clients improve their revenue
management and move forward on
their innovative journey with notable
speed.
CereSoft provides claims
presentment to the payer gateway
and accepts both ERAs and Paper
EOBs for processing. The company
matches and balances that
information with ACH/EFT
payments and paper checks.
CereSoft’s online portal processes
both co-pays and patient pays as they
are integrated into the CereSoft
Desktop Navigation System.
The company provides a
SingleTOUCH Methodology under a
SingleVIEW.
the business document and process
renovation field. Dr. Chen envisioned
automating the healthcare RCM
process to integrate claim
submissions, payment adjustments,
cash posting and other necessary
business workflows.
He developed an intelligent process
to capture business data from
structured, semi-structured and even
fully un-structured documents,
including databases, electronic files,
business forms and paper
correspondence.
Dr. Chen’s visionary leadership has
positioned CereSoft as the company
to watch in this fast-evolving
industry.
Cutting-Edge Technology and
Innovation
The CereSoft system is field-proven
across both large- and small-scale
implementations and it has shown
that it is capable of meeting special
requirements and adapting to
customized business rules.
CereSoft is committed to integrating
leading edge technology and
innovative payment methods into its
flagship Payment Central Platform,
which includes features like checks,
mobile pay with image recognition
technology, document understanding
and artificial intelligence.
The company envisions employing
robotic process tools and block chain
technology to enhance the security
and efficiency of its intelligent
system.
Anyone with an
internet connection,
anywhere in the world
can access, monitor
and work using our
cloud-based platform.
This will provide
significant cost
reductions in the years
to come.
31
|
www.insightssuccess.com September 2020
34. ClinCapture
A Sweeping Wave of Big
Data Innovation in the
Pharmaceutical Industry
Todd Hu man
CEO & Co-founder
A
Few years ago, Mckinsey Global Institute
estimated that the application of big-data
strategies to improve decision making was capable
of generating over $100 billion in value annually across the
US health-care systems. This advanced decision making
made possible by cloud technology, improved analytical
methods was the next horizon of innovation on the block.
Today, this change is sweeping across the healthcare
landscape creating value and opening new territories for
innovation.
However, in order to benefit from this innovation it is
important for companies to optimize this innovation and
improve the efficacy of their current research methods and
trials simultaneously. This innovation opens up a
personalized array of solutions for patients supported by a
wide array of tools for physicians, consumers, insurers and
regulators.
A large part of this innovation is the role of Big data and it
is an opportunity unlike anything we have witnessed before.
Earlier the data generated from clinical trials under
controlled environment could be well documented.
However, with the advent of cloud solutions, pharma
companies can store data from various sources including
patient care, retail stores and caregivers as well. Of course,
all of this data must be HIPAA compliant. Applying this
data effectively will allow pharmaceutical companies to get
an insight into the industry to predict the rise of new patient
needs and develop effective drugs to reach new patients and
reach greater heights.
ClinCapture provides a powerful eClinical platform that
enables sponsors and CROs to rapidly build and deploy
studies, lower clinical trials costs, and streamline data
capture processes. Offering a host of private cloud
solutions, ClinCapture’s technologies help advance the
evaluation and development of drugs, biologics, and
devices that demonstrate promise for the diagnosis and/or
treatment of a wide range of diseases or medical conditions.
By bringing greater efficiency and accuracy into clinical
trials, ClinCapture serves the mantra, “Software that saves
lives!”
A vision - the Turning Point
CEO Scott Weidley joined the ClinCapture team at a pivotal
time in the company’s history. The company had recently
built Electronic Data Capture (EDC) software, but was also a
Scott Weidley
President & CEO
32 | www.insightssuccess.com
The 10 Most In luential Leaders in MedTech Companies, 2020
September 2020
35. professional services business. Weidley
saw the value of technology in the
clinical trials space, and felt that
customers were seeking solutions – not
services. From this vision, the Captivate
eClinical platform was born.
“Scott is the Marc Benioff of EDC,”
Ale Gicqueau, ClinCapture founder,
was quoted as saying at the time.
History seems to be proving him right,
as ClinCapture is now a leading
provider of eClinical software
solutions.
A Leading Innovator
From the beginning, ClinCapture has
set out to be different than what the
industry is used to. Its competitive and
technologically-advanced product is
setting new EDC industry standards,
giving customers a higher quality,
more affordable EDC alternative to
established industry leaders. For
example, Electronic Data Capture
(EDC) with Medical Coding integrates
a user-friendly interface that was built
on the same modern framework as
Facebook, Instagram, and Netflix and
includes a free build tool, and free
training and support. Additionally, it is
HIPAA, CFR 21 Part 11, and GDPR
compliant and the platform includes
Electronic Clinical Outcomes
Assessments (eCOA) / Patient
Reported Outcomes (ePRO) as well as
Randomization options for customers.
The company has pushed the limits
with both the brand and the product
alike. It believes in providing
innovative and high-quality Electronic
Data Capture (EDC) product at a
fraction of the cost of its leading
competitors. Its eClinical solutions
help advance the evaluation and
development of drugs, biologics, and
devices by bringing increased
efficiency and accuracy into the
clinical trials process, thereby allowing
pharmaceutical, biotechnology, and
diagnostic companies to bring products
to the market faster and at a lower cost.
Ultimately, these products may be life-
saving; this is the story behind the
mantra of the company, “Software that
saves lives!” ClinCapture’s customers
are creating medical advancements,
some of which may have life-saving
applications.
An Upcoming Bright Future
There are two or three big companies
in the eClinical space and ClinCapture
is committed to being on top in terms
of quality with these companies. It has
stayed true to its brand and its high-
quality product, which is increasingly
gaining popularity with clinical data
managers in the industry. When asked
about the future prospects of the
company, Scott said, “From big 3 EDC
to the gold standard in EDC? We are
on our way!”
He also added, “ClinCapture is
growing at a high velocity as we
continuously introduce new products.
Our primary goal is to continue to
provide our customers with the
highest-quality eClinical solutions at
the lowest price.” His statement
highlights a rapid advancement in the
industry.
According to the Mckinsey Global
Institute study, there are various
segments in the pharmaceutical
industry which are experiencing a
rapid growth. One such segment is
biopharmaceuticals. According to the
study, the rates of growth for
biopharmaceuticals is near 8%
annually and it is almost double that of
conventional pharmaceutical solutions.
In order to tap the growing potential
and demand in the pharmaceutical
industry, ClinCapture adopts a simple
approach to innovation. To summarize
it, Scott said, “Data is what makes it
work. We love our customers. We love
data managers!”
Our primary goal
is to continue
to provide
our customers
with the
highest-quality
eClinical solutions
at the
lowest price.
33
|
www.insightssuccess.com September 2020
36.
37.
38. CMIC Inc.
Leading Treasure in Healthcare Industry
Especially in Pharmaceutical Sector
harmaceutical sector is blooming at subsequently than ever being imagined.
PAnd only few companies proved themselves worthy of it. Meet, a CMIC, Inc.
leading CRO (Contract Research Organization) and a provider specialized in
bioanalytical services, whose cutting-edge capabilities and sophisticated expertise in
various aspects helped it achieve a greater stature in the business. Its bioanalytical
services are in support of TK/PK/PD Biomarker studies for pre-clinical and clinical
developments. It firmly focuses and holds expertise in bioanalytical method
development, method validation/qualification and study sample analysis for small,
large molecules and Oligonucleotide. The “CMIC” name originally stood for
“Current Medical Information Center”, and the company remains committed to the
advancement of medicines and healthcare revolution. As a strategic drug
development partner, CMIC helps sponsors to overcome challenges in bioanalysis
with expertise, rapid data turn-around-time, and high-quality customer services.
The company states its core values intercepted through, W & 3C;
Ÿ WELLBEING: Fully Live Every Moment
Ÿ Challenge: Liberate opportunity by changing our vantage point
Ÿ Change: Transform without seeking refuge in conventional wisdom
Ÿ Communication: Proactively reach out to sponsors, people and society
The Story behind CMIC
CMIC Inc. originated from CMIC Group, which is the very first and largest Contract
Research Organization (CRO) in Japan. Contract research organizations (CROs) have
become an integral part of drug discovery and development to support sponsors
research needs, expedite timelines and provide an extension of technical and
scientific support. CMIC has worked with the top 10 global pharma companies and
has been involved in and supported more than 80% of new drug development in
Japan.
CMIC, Inc. was established as a strategic cornerstone for CMIC Group’s North
America growth. It has the vision to provide a solution service as “Pharmaceutical
Value Creator” (PVC) that encompasses an entire value-chain of pharmaceutical
companies. The company has been the top bioanalysis CRO in oligonucleotide
therapeutics (Oligo) development for nearly a decade with strong proven expertise. It
also o ers 30+ years of experience in conventional & small molecule and are also
significantly expanding its capabilities in large molecule and biomarker Bioanalysis.
On account being di erent from other companies, it is leading bioanalysis CRO in
oligonucleotide therapeutics (Oligo) as well as very flexible and agile with quick
turn-around time on all services o ered, which is not possible by large CROs. In
addition, CMIC, Inc. together with the rest of CMIC Group has significant scientific
publications and whitepapers and had been the integrated players f supporting various
drug development e orts.
The 10 Most In luential Leaders in MedTech Companies, 2020
36 | www.insightssuccess.com
September 2020
41. A Glimpse into Jenny’s Life
Jenny Lin, Chief Operating O cer and Board Member. She holds
26 years of executive/lab management experience in bioanalytical
and analytical laboratory operations in support of drug discovery,
pre-clinical and clinical drug development. Moreover, she is
proficient in GLP, GMP, GCP, OECD, ICH and 21 CFR part 11
regulations and in business strategic planning and execution. Her
expertise includes building organizational quality system, sta
training, bioanalytical/analytical method development/validation,
bioanalytical sample analysis, analytical development for CMC
submission, chromatography purification, stability studies,
reference standard certification, QC support for GMP manufacture.
She has been also a selected member for Global Bioanalysis
Consortium (GBC) making recommendations for global
Bioanalysis harmonization. She serves as editorial board member
for peer reviewed journal and chair for international conferences.
Besides, she is an author and co-author for approximately 40
publications, white papers and presentations and is the inventor of
7 issued US patents. Jenny earned her BS in Analytical Chemistry
at Peking University and her MS in Medicinal Chemistry at
University of Connecticut. She is a member of the American
Society of Mass Spectrometry (ASMS), American Association of
Pharmaceutical Scientists (AAPS), American Chemical Society
(ACS), National Association of Professional Woman (NAPW) and
Global CRO Council (GCC).
Future of CMIC
CMIC and the CREED as corporate philosophy, consists of
Wellbeing, Challenge, and Communication (W&3Cs). The
company has been applying these items to continuously evolve
itself in line with market changes, and will do so in the future.
Moreover, by further expanding from the current “Pharmaceutical
Value Creator” (PVC) business model, the company has an
aspiration to become a “Personal Healthcare Value Creator”
(PHVC) to contribute for and to address to the up-coming
personalized medicine and individual patient quality of life.
“Our vision is to advance the
innovation of products and solutions
that will empower people worldwide
to achieve greater health and
well-being.”
39
|
www.insightssuccess.com September 2020
42. ENSU
HEALTH
EQU
We all bargain for a little more, everybody wants
a better life, we all know what success sounds
like, or is there something more to life?
Everybody loves a hero. During this pandemic period of
Coronavirus, healthcare workers are our real heroes. They
are the ones who inspire us to hold on for a little longer.
While the world was at a stop, they were the ones risking
their lives to save ours and they continue to do so. Will we
really achieve our dreams if there is no healthcare system in
any country? This article will evaluate the importance of
healthcare leaders in society.
Any crisis brings opportunities for improvement and
change. The current situation of Covid-19 makes us realize
the importance of the healthcare industry. This is an
opportunity for countries to increase expenditure on the
much-needed healthcare infrastructure. Conserving and
ensuring the well-being of the healthcare workforce is the
need of the hour. Even before this pandemic, the healthcare
system was considered the backbone of any country.
Healthcare infrastructure is not something that should come
to the limelight during an outbreak like Corona. A long-
term action, regarding the overall development of
healthcare infrastructure, should be the priority. The
frontline healthcare workers are to be provided with
40 | www.insightssuccess.com
September 2020
43. URING
HCARE
UITY infrastructural facilities so that they can do their part. It now
makes sense that the need for healthcare leaders and
providers are growing. The requirement for professionals to
manage healthcare facilities will also grow.
Till now there were two phases up to 1998 till 2010, during
which several hospitals were built. Then the health sector
was considered too expensive. Furthermore, there was also
a very relevant expansion of privatization. The end result
has been that in Italy and in some other European countries,
the improvement of hospitals was stopped. Awareness and
preparedness need to be elaborated to build the healthcare
environment. What is clear is that the decentralized health
system has been an issue.
The future of healthcare is shaping along with healthcare
technologies such as AI, robotics, and nanotechnology.
Healthcare leaders will have to embrace change in order to
stay relevant in the coming years.
Hence, we can conclude that the importance of the health
facility systems and hospitals should be given priority.
Healthcare leaders are making miracles in adapting to the
dramatic complexities of any situation. This is only a
shortlist of continuous and constant management. This way,
we would respect the healthcare leaders.
41
|
www.insightssuccess.com September 2020
Tech View
44.
45.
46. ‘‘ Jan Miotto
President
Metrendalytics
The 10 Most In luential Leaders in MedTech Companies, 2020
Pharmaceutical services
consulting and software
development company,
focused on helping both
pharma and CRO's
centralize operational
data for real-time use.
44 | www.insightssuccess.com
September 2020
47. etrendalytics was founded by scientists, for
Mscientists. Our goal is to provide integrated
solutions which provide a consolidated view of
all of one's operational data—whatever the source—on one
shared platform for faster interactive collaboration and
client service with reduced risk.
Metrendalytics recognizes that companies need a platform
to create comprehensive efficiencies across project planning
and execution with built-in analytic tools that are easy to
implement, are highly customizable, and cost-effective. To
enable this transformation journey to optimize “running the
laboratory business” with technology requires innovative
business solutions uniquely designed and customized
around a company's specific business model and processes.
Metrendalytics works to understand and build systems to
meet the unique process needs of each company. Then we
enhance the resultant process efficiency with corresponding
operational dashboard views with automated data
integration, aggregation, and signal detection in interactive
visualizations, which allows for centralized views and
remote monitoring of project performance in real-time.
Reviewers are able to zero in on signals and trends that
could affect operational performance and make smarter
decisions sooner about how to deploy resources. This
eliminates error prone, redundant entry and information
update lag time associated with typical business
management via various spreadsheets used for tracking of
these activities which are a basis of vast inefficiencies. As a
result, companies are essentially road blocked in the ability
to unleash the power buried in their operational data.
Metrendalytics' solutions have been presented at multiple
pharma/biotech meetings and conferences over the years.
Many of these presentations were from its customers. Most
recently, it was featured in a Bioanalysis Zone article on
how Metrendalytics' remote access solutions helped
businesses continue and thrive through the Covid-19
pandemic.
Extensive Service Offerings
Metrendalytics is a Pharmaceutical consulting services and
software development company focused on helping
pharma/biotech clinical operations and CRO's laboratory
operations centralize operational data for real-time use. The
company utilizes cloud-based, scalable, modular, rapid
development, and low-cost platforms which are analytics
and visualization enabled. The key to success is its software
combines existing internal and external data into a single
platform allowing customers to gain efficiencies and make
faster, more informed decisions. As a result, the firm helps
transition a business from a process that is reactive to one
that is more proactive.
The laboratory tools and technologies in the bioanalytical
laboratory have evolved and changed. However, leveraging
real-time business data to make more informed decisions
has seen limited progress. Further, additional time is
required to manually create plots and metric reports to be
used for analytics and process improvement initiatives. As a
result, less time is available for analyzing data to improve
business outcomes, customer service, and risk reduction.
Metrendalytics' software integrates the information from
existing software like Salesforce, Watson, NetSuite, etc and
incorporates these into a suite of applications to centralize
from proposal creation, award, and management of
milestones and deliverables through QC, QA, and reporting.
This provides a “one-stop-shop” for all critical business
functions and data so that each stakeholder has what they
need to efficiently complete their part. This means
laboratory and management personnel can spend more time
doing science and serving customers instead of chasing data
and re-entering information.
Passion and Expertise
Jan Miotto, President of Metrendalytics, had a successful
career in the drug development industry because of her
ethics of hard work and wanting to make things better for
the industry. This, along with a lifelong passion to learn and
apply new technologies is what drives the success of
Metrendalytics. She has assembled a group of like-minded
successful individuals who work together with the goal of
making customers successful.
METRENDALYTICS
Combining Knowledge and Technology to Bring Efficiency in Business
45
|
www.insightssuccess.com September 2020
48. Jan focuses on being authentic and bringing
value every day and trying her best not to
keep a fixed mindset in order to be able to
explore new opportunities. Jan says, “If you
wait for things to be perfect, you can miss
opportunities.” She brings a mindset to
never stop adapting. For Metrendalytics,
experimentation has helped them reach a
product-market fit.
Driving Improvement by Knowing Your
Customer
Metrendalytics' culture is to really partner
with its clients to help take them to the next
level. “We work with our customers to
understand their business, their pain points,
and where they want to be in the future,”
says Jan. Being knowledgeable in the
industry allows the company to understand
each client's specific situation and allowing
it to be flexible to design the tools they need
to be successful. The goal is to add value
and transparency to all levels of the
organization.
Metrendalytics aims to improve the “life of
the scientist in the laboratory” by providing
tools to leverage already existing
information. It helps mid-level managers
drive improvement gains through
automated capture of metrics and trends. It
also provides senior-level executives up to
the minute visibility to their entire portfolio
to understand the current status of their
projects and where action is needed to keep
programs on track. By being more efficient
with information, the company helps all
levels of the organization perform better to
help take time and cost out of the drug
development process.
Current Crisis and Future Opportunities
Metrendalytics has always been at the
forefront when it comes to how it uses the
information to improve business results. It
will continue to do so in the future. The
recent Covid-19 pandemic has accelerated
the adoption of cloud-based and remotely
accessed information systems. The
company will build on its past success in
this area to develop new and expanded
46 | www.insightssuccess.com
September 2020
49. capabilities to meet the full-service needs of its customers.
The company asserts “Our low cost, rapid development
model also makes replacing some of the disconnected and
more expensive “point solution” systems possible.”
Metrendalytics continues to build a network of experienced,
results-oriented subject matter experts in the laboratory,
drug metabolism, and chemistry manufacturing and
controls. This expanded knowledge base provides access to
new markets and the opportunity to leverage its technology
to benefit these areas.
Socially Responsible
Metrendalytics is active in Corporate Social Responsibility
including philanthropy, environment conservation, diversity
and labor practices, and volunteerism. As a company,
Metrendalytics is diverse and designated as a female-
owned, minority business and some of its partners are also
minority-based.
It has donated time and resources to start-up groups and
technology companies that share the same passion for data
and using that data to build the next-generation laboratory
or improving upon existing technology to help the day-to-
day work life of the scientist.
On Drug Development Challenges
Drug development is a long and costly process typically
requiring approximately 10 years and hundreds of millions
of dollars. By developing solutions that reduce this time and
cost, Metrendalytics not only saves money for customers
but also helps get products to market faster. As a result, the
public has access to potentially life-saving medications
sooner. This in turn provides a revenue stream for the
pharma company to reinvest in future drug development.
For CROs, where the name of the game is efficiency and
value, here again, Metrendalytics helps to improve both of
these. The more efficient the resources are in a CRO, the
more projects can be completed, which accelerates drug
development as noted above. It also means better
profitability and stability for the CRO.
For both CROs and pharma biotech companies, the time
saved translates to more focus on the actual work of drug
development instead of time wasted collecting and
managing information. That time saved can then channelled
into value-added activities like quality control, assessment
and impact analysis or actions or innovations to improve
the outcome.
Testimonials from Clients
“Jan and her team at Metrendalytics collaborated with our
team at Alturas Analytics to create a total customized
information management system that organizes and
manages client information, data and resource
management. The system has improved productivity,
efficiency and compliance in our bioanalytical CRO. Thank
you Metrendalytics!”
-Shane Needham, Co-Founder and Chief Scientific
Officer at Alturas Analytics, Inc.
“Immunologix Labs is accelerating our bioanalytical
service delivery to the technology forefront with the
Metrendalytics initiative. The platform will be our primary
driver for industry-leading efficiency, organization and
client experience. It will provide the architecture to
seamlessly ensure consistent, high-quality, on-time
performance for our clients. We are very enthusiastic about
our partnership with Jahanara (Jan) Miotto and the team at
Metrendalytics"
-Michael Anderson, President and Chief Executive
Officer at Immunologix Laboratories
“We are on an exciting journey with Metrendalytics in
moving from a paper heavy lab to a paper-lite lab to a
paperless lab, which will enhance the efficiency of the
entire laboratory process, leading to a dramatic overall
cost reduction in operations and a better way to work for
everyone. Many thanks to Metrendalytics in bringing our
vision into reality”
-Luca C Matassa, VP and Head of Bioanalytical at QPS
Laboratoriese operational data for real-time use”
47
|
www.insightssuccess.com September 2020
50. Triox Na
Pioneers in point of care programmable medicine! presenting th
n an interview with Insights Success, Triox Nano's
Imanagement describes its impeccable journey to
become the first biotech company to develop a
modular programmed drug delivery platform. The
company's revolutionary technology, termed S.M.A.R.T, an
acronym for Stimuli Multi Adjusted Responsive
Technology, or simply put “Programmable medicine” is
based on combinations of DNA coding, DNA molecular
machines and mesoporous nanoparticles. SMART offers the
potential to add programming to almost any approved
medicine that may in turn increase its efficacy
exponentially.
Prominent opinion leaders and investors had been funding
TrioxNano's development to date including the European
commission through the prestigious H2020 Horizon
program. Competing with over 1500 companies
TrioxNano's technology won a non diluting grant of
roughly $2.5 million USD. TrioxNano's all inclusive patents
are granted around the world . Many believe this
breakthrough technology may lead the way to the next
healthcare revolution!
To create S.M.A.R.T Triox Nano had to first invent the
modular hardware that will allow incorporation of many
different medications, the software language which is based
on DNA coding and the actual codes that will control the
nano particle. The technology is expected to create a
paradigm shift and highly impact human lives around
the globe, transforming medicine from its current primitive
analog state to a programmable digital modern era.
S.M.A.R.T creates a vast field of programmable
nanoparticles that can deliver their payload to target tissues
based on the software code that is uploaded to them. The
final commercialized product is expected to be supplied
with a list of common software codes. The treating
physician will decide which codes to use and will easily
upload them to the modular nanoparticle that incorporates
the relevant medication. The doctor will have the option to
upload a mixture of several codes into the same treatment
based on the patient's clinical and pathologic profile.
Under the supervision of Joseph Farfara, Triox Nano's
CEO, the company has progressed robustly in the last 3
years, broadening the type of medications that can be
loaded into the platform, improving the capping
characteristics and securing its IP with patents granted
around the world.
Below are the highlights of the interview:
Can you explain to our readers what so exciting about
Triox Nano work?
Joseph Farfara, Triox Nano's CEO “By the year 2020,
thousands of APIs (Active Pharmaceutical Ingredients) had
been developed to treat different diseases, yet not even one
efficient modular technology was developed to deliver them
accurately to their target! The most efficient way to do this
is use programming abilities so that each API can have tens
of programs to direct it to different targets upon request. If
you compare this to the car industry its like everyone has
been developing thousands of types of engines without
finding a way to connect them to the wheels yet. Current
delivery methods, such as Injections or tablets deliver only
a small percentage of their original doses to the tissues
requiring treatment, and instead, most of the dose arrives to
healthy tissue causing severe toxicity.
Examples for our programing abilities include the TXN770
family of nanoparticles intended for the treatment of TNBC
(Triple Negative Breast Cancer). TXN770 combines
between a modular unit loaded with the chemotherapy
doxorubicin, that is already approved for the treatment of
TNBC and the ability to be programmed by a combination
of different software codes that control its release according
to common traits found in the patient's specific tumor such
as high levels of Magnesium and high levels of ATP. Other
programing options we are developing include high levels
48 | www.insightssuccess.com
The 10 Most In luential Leaders in MedTech Companies, 2020
September 2020
51. ano
he next healthcare revolution!
Roy Farfara, MD
Founder & CTO
of PD1, PARP and Nucleolin found to be high in subgroups
of TNBC patients. This allows us to use the same modular
particle that includes Doxorubicin and program it to react to
different cancer traits. In parallel we have created other
modular particle loaded with the chemotherapies
Mitoxantrone and Docetaxel (that is approved already for
TNBC) that can use the same software codes described
above (Mg, ATP, PD1, PARP, Nucleolin).
We are focusing on TNBC Triple Negative Breast Cancer to
prove our technology's benefits but expect it to be relevant
for many other indications. We offer specific licenses to
the use of our S.M.A.R.T platform loaded with the
client's APIs (active pharmaceutical ingredient). This is
relevant for many types of companies, those who have a
medication that is effective but proven to be too toxic to be
used, or for medications that require high doses to be
effective, or in cases patent cliff issues have to be avoided.
Our standard license agreements includes milestone
payments and royalties fees, we offer our services for a fee
to develop the asset until completion of the of In Vitro
phase, expecting the companies to complete the In Vivo Tox
and clinical trials.
What led to the inception of Triox Nano?
Answer Dr. Roy Farfara CTO and founder of
TrioxNano
The inception of TrioxNano was at 2 AM after a long
operation of a young kidney cancer patient. Our department
was regularly accepting patients that other surgeons had
given up on operating them due to the technical difficulties.
We had the best techniques and technologies in Israel at the
time (biologic glues, mannitol, hypothermia) we were
taking out carefully tumor after tumor in the renal. We
finished the surgery exhausted though we knew we did the
best that can possibly be done. The patient kidney was not
resected, we managed to take out all tumors and substantial
bleeding avoided. Yet we understood that the patient ended
49
|
www.insightssuccess.com September 2020
52. up having less than %20 of the original kidney parenchyma
meaning he would most probably need dialysis in the near
future. My grandfather Simon Farfara RIP who was an
artisan taught me when I was a child that "The first step in
every challenge is to find the best tools to complete it".
Understanding that it is not possible that in the year 2013
we are trying to resect micron (one millionths of a meter)
size cancer cells with centimeter size knifes while on the
other hand treating with chemotherapy that is not specific
enough thus causing substantial side effects. Being aware of
the limitation of surgery (trying to resect micro meter size
cancer cells with inch size knifes) and the limitations of non
specific chemotherapies causing substantial toxicity made
me understand at that moment that we are totally not using
the right tools to achieve this goal, and set me out on this
journey”
Describe Triox Nano and its cutting-edge technology.
Answer Dr. Ehud Saas head of biologic programming
Interestingly computers have been incorporated into
everyaspect of our lives except medicine. TrioxNano has
developed and patented a programmable nano delivery
platform that can carry different medications, including
chemotherapies, to their target tissue. The technology uses
nanoparticles based on DNA machinery. These amazing
machines are made from single-stranded DNA and RNA
and allow us to program a modular particle with almost
infinite possibilities. Once completed, the technology will
enable the treating physician to upload the relevant DNA
module per individual patient and precise the administered
treatment based on his specific cancer traits. It is estimated
that more than 1000 approved medication can be delivered
by this programmable system and at least 500 unique
programmed modules can be uploaded to them. This adds
up to about half a million different options of unique
treatments (in the case that only one code is uploaded per
particle), in the case a combination of three codes is loaded
and estimated 125 billion treatment options are created.
As a leading pharma and biotech solution providers, what
contribution has been made by you?
Answer by Dr. Ofer Nusbaum head of chemistry biology
interface.
TrioxNano is trying to create a paradigm shift in the way
we treat disease. Programming is urgently need to enhance
the treatment of patients. In the case of Cancer as an
example, cancer cells develop different mutations in
different organs of the same patient. On the other hand
different cancer type share common pathways. For example
the PD1 pathway is relevant for a small percentage of
TNBC patients and larger percentage in many other cancer
types, many are being treated with PD1 inhibitors. This
translate into a need for modular programmed platform that
can relate to common traits in different tumors and different
mutation in the same patient. We believe we will be able to
offer the world the first modular programmable nano
delivery platform where the physician will be able to
program the medicine he gives his patient, he will choose
from a list of software codes that we will offer commercialy
and upload it to an armantarium of medication he can
choose from. Later on we plan to offer specific
programming to less common cases that require specific
softwares. Of note is that all the different chemotherapies
are packed in the same modular nanoparticle.
Describe in brief about the work culture and the values
that drive Triox Nano.
Joseph Farfara, Triox Nano's CEO
TrioxNano is driven by a team of highly intelligent hard
working open minded scientist. All our staff have hands on
experience of years in the industry. We are roughly divided
to chemists and biologists that are integrators able to bridge
the gap between these two worlds. As an Israeli company
we try to think out the box and “cut to chase” as much as
possible basing our decision on sound science.
What are the future aspirations of Triox Nano? What
strategies are you undertaking to achieve those goals?
Answer Dr. Roy Farfara CTO and founder of
TrioxNano
TrioxNano aspires to be the next Microsoft and IBM, on
one hand creating "the operating system for computerized
drug delivery" and on the other developing the hardware
required to run the operation system and the code. We want
to revolutionize the way patients are treated! To achieve this
“Triox Nano’s technology offers a paradigm shift that will highly impact
human lives, transforming medicine from an analog state to an
exciting programmable digital modern era”
50 | www.insightssuccess.com
September 2020
53. “It is estimated that more than 1000 approved medication can be delivered by this
programmable system and at least 500 unique programs can be uploaded to them.
This adds up to about half a million different options of unique treatments (in the
case that only one code is uploaded per particle), in the case a combination of three
codes is loaded and estimated 125 billion treatment options are created."
goal our strategies include a hybrid business model where
we develop our own drug candidate TXN770 (as a proof of
concept) for the treatment of TNBC but are actively
persuing to cooperate with others to incorporate their APIs
(Active Pharmaceutical Ingredients) into our modular
computerized platform.
How are you solving your customers' complex drug
discovery challenges?
Answer Dr. Roy Farfara CTO and founder of
TrioxNano
By incorporating their APIs into TrioxNano's S.M.A.R.T
platform, our partners may be able to increase efficacy
while using smaller doses, creating decreased toxicity, new
IP and an exponential increase in value. This cooperation
will importantly benefit humanity as thousands of
medications can be improved which translate into
improving human lifes!
What is your idea of Corporate Social Responsibility?
Joseph Farfara, Triox Nano's CEO
The hebrew saying "KOL HAMEZIL NEFESH ACHAT
KEILU HEZIL OLAM U MELO'O," meaning he who
saves one life is considered to save the world entire.
www.Smartriox.com
Joseph@TrioxNano.com
51
|
September 2020
www.insightssuccess.com
